Antihormonal treatment with or without whole breast irradiation in low risk breast cancer patients after breast conserving surgery: 10-year results of the ABCSG 8A trial

Fastner, G; Sedlmayer, F; Widder, J; Metz, M; Geinitz, H; Kapp, K; Solkner, L; Greil, R; Jakesz, R; Gnant, M BREAST. 2019; 44: S79-S79.

Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy

Papakonstantinou, A; Matikas, A; Hellstrom, M; Johansson, H; Steger, G; Greil, R; Loibl, S; Gnant, M; Moebus, V; Untch, M; Foukakis, T; Bergh, J ANN ONCOL. 2019; 30: 86-+.

The melastatin-like Transient-Receptor-Potential-7 protein regulates Cyclooxygenase-2 expression in human myeloid leukemia cells

Hampe, S; Nadolni, W; Holting, K; Fraticelli, M; Addington, L; Steinritz, D; Chubanov, V; Boekhoff, I; Breit, A; Greil, R; Gudermann, T; Zierler, S ACTA PHYSIOL. 2019; 227:

POSTTRANSPLANT OUTCOMES IN ALLOGENEIC AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN AUSTRIA IN COMPARISON TO THE EBMT BENCHMARK: A RETROSPECTIVE ANALYSIS OF THE AUSTRIAN SCT REGISTRY (ASCTR) 2000-2017

Bohm, A; Lindner, B; Rabitsch, W; Kalhs, P; Worel, N; Clausen, J; Nachbaur, D; Neumeister, P; Panny, M; Keil, F; Russ, G; Eder, S; Isak, E; Zojer, N; Burger, S; Greinix, H TRANSPL INT. 2019; 32: 20-20.

Therapy line and associated predictors of response to PD-1/PD-L1 inhibitor monotherapy in advanced NSCLC – a retrospective bi-centric cohort study

Lang, D; Huemer, F; Rinnerthaler, G; Horner, A; Wass, R; Brehm, E; Akbari, K; Granitz, M; Hutarew, G; Kaiser, B; Greil, R; Lamprecht, B WIEN KLIN WOCHENSCHR. 2019; 131(19-20): 521-522.

Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry

Gampenrieder, SPP; Rinnerthaler, G; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R ANN ONCOL. 2019; 30: 126-+.

B-cell specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhancing tumor immune evasion

Asslaber, D; Qi, Y; Maeding, N; Denk, U; Hopner, JP; Hartmann, TN; Zaborsky, N; Greil, R; Egle, A ONCOL RES TREAT. 2019; 42: 17-18.

Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial.

Wainberg, ZA; Lassen, UN; Elez, E; Italiano, A; Curigliano, G; De Braud, FG; Prager, G; Greil, R; Stein, A; Fasolo, A; Schellens, JHM; Wen, PY; Boran, AD; Burgess, P; Gasal, E; Ilankumaran, P; Subbiah, V J CLIN ONCOL. 2019; 37(4):

Induction chemotherapy with Docetaxel, Cisplatin and Cetuximab results in improved response rates if compared to Docetaxel, Cisplatin and 5-FU for locally advanced or inoperable squamous cell carcinoma of the head and neck: promising results of the Austrian multicentric phase II trial (AGMT)

Keil, F; Hartl, M; Altorjai, G; Pecherstorfer, M; Berghold, A; Riedl, R; De Vries, A; Mayrbaurl, B; Fridrik, MA; Fureder, T; Burian, M; Greil, R ONCOL RES TREAT. 2019; 42: 56-57.

First data on overall survival of metastatic breast cancer patients in Austria according to breast cancer subtype: results from the AGMT MBC Registry

Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R ONCOL RES TREAT. 2019; 42: 40-40.